Strategic exit ALung Technologies was acquired by LivaNova in 2022 for $10 million with potential sales-based milestones. This suggests channel and distribution shifts may open partnership opportunities with LivaNova’s legacy and new channels, as well as potential collaborations or licensing arrangements for Hemolung RAS technology.

Financial runway With total funding of $113M and a revenue range of $1M–$10M, the company demonstrates substantial early-stage capital and growing demand signals. This indicates potential for health-tech partnerships, contract manufacturing, and joint sales initiatives to scale adoption of the Hemolung RAS.

Clinical need Hemolung RAS targets acute respiratory failure scenarios such as COPD exacerbations and ARDS, offering a less invasive alternative to mechanical ventilation. This creates sales opportunities with hospital systems, ICUs, and pulmonary centers seeking to reduce intubation rates and ventilation-associated risks.

Market positioning The niche focus on respiratory dialysis and ultra-protective ventilation highlights a specialized product with potential to complement existing ECMO or ventilator programs. Sales plays could target tertiary care centers, academic medical centers, and regional procurement for critical care equipment.

Expansion potential Past acquisitions and financing rounds suggest ongoing growth ambitions and willingness to engage in strategic partnerships. Opportunities exist for OEM collaborations, distribution agreements, and regional deployments in markets where ALung’s technology can be integrated with current critical care workflows.